Maxigen Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
For the nine months, sales was TWD 440.12 million compared to TWD 370.65 million a year ago. Net income was TWD 96.13 million compared to TWD 73.89 million a year ago. Basic earnings per share from continuing operations was TWD 1.0823 compared to TWD 0.9004 a year ago. Diluted earnings per share from continuing operations was TWD 1.0736 compared to TWD 0.9004 a year ago.